Increased levels of interleukin-10 and transforming growth factor-β in the plasma and ascitic fluid of patients with advanced ovarian cancer

Berek, 1984, Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer, Obstet Gynecol, 64, 708 Gotlieb, 1992, Presence of IL-10 in the ascites of patients with ovarian and other intra-abdominal cancers, Cytokine, 4, 385, 10.1016/1043-4666(92)90082-3 Ioannides, 1993, T cell recognition of human tumors: implications for molecular immunotherapy of cancer, Clin Immunol Immunopath, 66, 91, 10.1006/clin.1993.1012 Hirte, 1991, Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor β as a suppressive factor, Cancer Immunol Immunother, 32, 296, 10.1007/BF01789047 Santin, 1999, Secretion of vascular endothelial growth factor in ovarian cancer, Eur J Gynecol Oncol, 3, 177 Rabinowich, 1998, Lymphocytes apoptosis induced by Fas-ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor associated lymphocytes, J Clin Invest, 101, 2579, 10.1172/JCI1518 Loercher, 1999, Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells, J Immunol, 163, 6251, 10.4049/jimmunol.163.11.6251 Massague, 1990, The transforming growth factor-β family, Annu Rev Cell Biol, 6, 597, 10.1146/annurev.cb.06.110190.003121 Berchuck, 1992, Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-β, Am J Obstet Gynecol, 166, 676, 10.1016/0002-9378(92)91697-9 Tada, 1991, Transforming growth factor -β induced inhibition of T cell function, J Immunol, 146, 1077, 10.4049/jimmunol.146.3.1077 Gray, 1994, The role of transforming growth factor β in the generation of suppression: an interaction between CD8+ T and NK cells, J Exp Med, 180, 1937, 10.1084/jem.180.5.1937 Moore, 1993, Interleukin-10, Annu Rev Immunol, 11, 165, 10.1146/annurev.iy.11.040193.001121 de Vaal Malefyt, 1991, Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression, J Exp Med, 174, 915, 10.1084/jem.174.4.915 Taga, 1993, Human interleukin-10 can directly inhibit T-cell growth, Blood, 81, 2964, 10.1182/blood.V81.11.2964.bloodjournal81112964 Santin, 2000, Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid eluted peptide pulsed autologous dendritic cells, Obstet Gynecol, 96, 422, 10.1016/S0029-7844(00)00916-9 Santin, 2000, Induction of tumor-specific HLA class I restricted CD8+ cytotoxic T lymphocytes by ovarian-tumor antigen pulsed autologous dendritic cells in patients with advanced ovarian cancer, Am J Obstet Gynecol, 183, 601, 10.1067/mob.2000.107097 Staveley-O'Carrol, 1998, Induction of antigen-specific T cell anergy: an early event in the course of tumor progression, Proc Natl Acad Sci USA, 95, 1178, 10.1073/pnas.95.3.1178 Horiguchi, 1999, Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alteration in signal transduction in T cells and NK cells, Cancer Res, 59, 2950 Merogi, 1997, Tumor-host interaction: analysis of cytokines, growth factors, and tumor infiltrating lymphocytes in ovarian carcinomas, Hum Pathol, 28, 321, 10.1016/S0046-8177(97)90131-3 Kim, 1995, IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response, J Immunol, 155, 2240, 10.4049/jimmunol.155.4.2240 Takeuchi, 1997, On the mechanisms by which TGF-β 2 alters antigen presenting ability of macrophages on T cell activation, Eur J Immunol, 27, 1648, 10.1002/eji.1830270709 Letterio, 1998, Regulation of immune responses by TGF-β, Ann Rev Immunol, 16, 137, 10.1146/annurev.immunol.16.1.137 Allavena, 1998, IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages, Eur J Immunol, 28, 359, 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4 Merville, 1992, Serum interleukin-10 in early stage multiple myeloma, Lancet, 340, 1544, 10.1016/0140-6736(92)92795-H Blay, 1993, Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor, Blood, 82, 2169, 10.1182/blood.V82.7.2169.2169 Maeda, 1995, TGF-β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice, J Immunol, 155, 4926, 10.4049/jimmunol.155.10.4926 Halak, 1999, Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at tumor site, Cancer Res, 59, 911 Melichar, 1998, Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis, Clin Cancer Res, 4, 799 Shirai, 1992, Elevated levels of plasma transforming growth factor β in patients with hepatocellular carcinoma, Jpn J Cancer Res, 83, 676, 10.1111/j.1349-7006.1992.tb01964.x Ivanovic, 1995, Elevated plasma levels of TGF-β in patients with invasive prostate cancer, Nat Med, 1, 282, 10.1038/nm0495-282 Punnonen, 1998, Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors, Cancer, 83, 788, 10.1002/(SICI)1097-0142(19980815)83:4<788::AID-CNCR24>3.0.CO;2-N Assoian, 1986, Type β transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells, J Cell Biol, 102, 1217, 10.1083/jcb.102.4.1217 Green, 1996, Hypercoagulability in cancer, Hematol/Oncol Clin North America, 10, 499, 10.1016/S0889-8588(05)70349-X Zeimet, 1994, Significance of thrombocytosis in patients with epithelial ovarian cancer, Am J Obstet Gynecol, 170, 549, 10.1016/S0002-9378(94)70225-X Kyrtsonis, 1998, Serum transforming growth factor-beta is related to the degree of immunoparesis in patients with multiple myeloma, Med Oncol, 15, 124, 10.1007/BF02989591 Ahuja, 1993, Effect of transforming growth factor-β on early and late activation events in human T cells, J Immunol, 150, 310, 10.4049/jimmunol.150.8.3109 Taga, 1992, IL-10 inhibits human T cell proliferation and IL-2 production, J Immunol, 148, 1143, 10.4049/jimmunol.148.4.1143 Hsu, 1996, Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells, Nature Med, 2, 52, 10.1038/nm0196-52 Nestle, 1998, Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells, Nature Med, 4, 328, 10.1038/nm0398-328 Thurner, 1999, Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melnoma, J Exp Med, 190, 1669, 10.1084/jem.190.11.1669 Kugler, 2000, Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cells hybrid, Nature Med, 6, 332, 10.1038/73193